Allergan successfully completes Kythera acquisition
KYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreTag: Submental Fat
ATX-101: Non-surgical reduction of submental fat
Klaus Hoffmann reviews the results of phase I, II, and III clinical studies using ATX-101 for the reduction of submental fat and discusses its potential use in clinical practice
Read MoreATX-101 shows further promise for reduction of chin fat in clinical trials
Skin laxity and fat build-up under the chin is a common concern among facial aesthetic patients. Although surgery has long been the mainstay for reducing fat in this area, which...
Read MoreFirst topical pharmacologic therapy to enter clinical trials for ‘double chin’
Topokine Therapeutics has initiated dosing in a Phase 2, randomised controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly referred to as ‘double chin’. XAF5 Gel...
Read More
September/October 2023 Issue
